BioArctic AB (STO:BIOAB), a Swedish research-based biopharmaceutical company, announced on Wednesday that the first clinical study with ABBV-0805 has started in the US.
Reportedly, biopharmaceutical company AbbVie Inc (NYSE:ABBV) is responsible for the clinical development of ABBV-0805. This phase 1 study in healthy volunteers will investigate the safety and tolerability of ABBV-0805.
According to the company, ABBV-0805 is the most advanced within the portfolio of alpha-synuclein targeting antibodies in-licensed by AbbVie from BioArctic in December 2018. This antibody is being evaluated as a disease modifying treatment for Parkinson's disease.
ABBV-0805 is a result of a strategic research alliance between BioArctic and AbbVie focused on the development of a potential immunotherapy for Parkinson's disease.
BioArctic is focusing on disease-modifying treatments and reliable biomarkers and diagnostics for neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. The company also develops a potential treatment for Complete Spinal Cord Injury.
ConnectedLife and Ocean Protocol partnership to combat Parkinson's Disease
Evolution Research Group names new chief operating officer and chief business officer
Actinium Pharmaceuticals names new vice president, global head of Regulatory Affairs
Ono Pharmaceutical signs drug discovery research collaboration contract with twoXAR
Bicycle Therapeutics Names Legault as New Director and Board Chairman
Mayo Clinic Collaborates with GIBLIB to Broaden Medical Education Accessibility Worldwide
Karuna Therapeutics Closes USD 68m Series B Financing
Oragenics Enrolls 60th Patient in Clinical Trial
Enigma Biomedical Inks License Agreement with US Merck for Novel MK-6884 Imaging Agent